Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). The firm is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The firm's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The firm's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.
Follow-Up Questions
Quelle est la performance du prix de l'action GLMD ?
Le prix actuel de GLMD est de $1.19, il a increased de 0.09% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Galmed Pharmaceuticals Ltd ?
Galmed Pharmaceuticals Ltd appartient à l'industrie Biotechnology et le secteur est Health Care
Quel est la capitalisation boursière de Galmed Pharmaceuticals Ltd ?
La capitalisation boursière actuelle de Galmed Pharmaceuticals Ltd est de $6.5M
Est-ce que Galmed Pharmaceuticals Ltd est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 3 analystes ont établi des notations d'analystes pour Galmed Pharmaceuticals Ltd, y compris 0 achat fort, 0 achat, 3 maintien, 1 vente et 0 vente forte
